search
Back to results

Impact of Insecticide-treated Curtains on Antimalarial Drug Resistance

Primary Purpose

Malaria

Status
Completed
Phase
Not Applicable
Locations
Burkina Faso
Study Type
Interventional
Intervention
Chloroquine
Sponsored by
London School of Hygiene and Tropical Medicine
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Malaria focused on measuring Transmission intensity, Insecticide-treated materials, antimalarial drug resistance

Eligibility Criteria

6 Months - 59 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age between 6 and 59 months Mono infection with P.falciparum malaria, with parasitaemia in the range of 1,000 to 150,000 parasites per ml Absence of danger signs or signs of severe malaria. Axillary temperature >= 37.5 ºC. Absence of signs of severe malnutrition. Absence of any obvious cause of fever other than malaria. No history of allergy to CQ. Willingness to return to the health facility for follow-up. Informed consent obtained from the caretaker of the child Exclusion Criteria: Danger signs of severe or complicated malaria, persisted vomiting. Received treatment with an antimalarial drug other than CQ in the last 2 weeks. Caretaker did not sign the consent form

Sites / Locations

  • Centre National de Recherche et de Formation sur le Paludisme

Outcomes

Primary Outcome Measures

Clinical and parasitological failure rates by day 14
Prevalence of pfcrt-76T, pfmdr1-86Y before treatment

Secondary Outcome Measures

Proportion of children who cleared parasites carrying pfcrt-76T and pfmdr1-86Y alleles.
Prevalence of dhfr-51, 59, 108 and dhps-437, 540

Full Information

First Posted
September 9, 2005
Last Updated
January 11, 2017
Sponsor
London School of Hygiene and Tropical Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT00169078
Brief Title
Impact of Insecticide-treated Curtains on Antimalarial Drug Resistance
Official Title
A Study of the Impact of Insecticide-treated Curtains on the Prevalence of Antimalarial Drug Resistance in Children With Uncomplicated Malaria in Burkina Faso
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
July 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2002 (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
London School of Hygiene and Tropical Medicine

4. Oversight

5. Study Description

Brief Summary
Attempts to understand the relationship malaria transmission intensity and antimalarial drug resistance had rested mainly on mathematical models. To date, except for two studies which reported reductions in the prevalence of drug resistance in Tanzania and Zimbabwe, no other field data addressed the impact of reducing malaria transmission by the use of vector control measures on antimalarial drug resistance. Thus whether vector control decrease or increase drug resistance remains a contentious issue. The aim of this study was to investigate the impact of insecticide-treated curtains (ITCs) on clinical and parasitological outcomes in children with uncomplicated malaria treated with chloroquine (CQ), on the prevalence of genetic markers of resistance to CQ and sulphadoxine-pyrimethamine (SP) and on the ability of children to clear drug resistant parasites. The therapeutic efficacy of CQ was studied in 9 villages which used ITCs for 6-8 years and 9 villages with no history of ITC use. A cross-sectional survey was also conducted to estimate the prevalence of genetic markers of resistance to CQ and SP in asymptomatic children.
Detailed Description
Background Drug resistance has been associated with increased numbers of hospital admissions, increased cases of clinical malaria and malaria-specific mortality . Several strategies have been proposed as means by which the spread of antimalarial drugs resistance could be delayed. These strategies include reducing drug pressure, improving the quality of drug use, using combinations of antimalarial drugs and use of vector control measures. Restricting the use of drugs to reduce drug pressure is presently unrealistic due to poor access to health facilities and a lack of equipment. Improving the quality of use of antimalarials through the use of pre-packaged doses, education and training is a sound control strategy. However, the impact of this strategy on drug resistance has not yet been evaluated. Another promising approach to contain drug resistance is the use of combination therapies. The most successful combinations so far are those using artemisinin and its derivatives. It is likely that implementing combination therapy in resource limited countries will be hampered by its high cost. Given their impact in reducing malaria transmission, cases of clinical malaria and all-cause malaria mortality, insecticide-treated materials (ITMs) have recently been proposed as a potential tool for delaying the development and spread of drug resistance. So far, the debate on the interaction between malaria transmission intensity and drug resistance has been driven by analytical models and, to our knowledge, only 2 field studies have yet addressed the impact of ITMs on antimalarial drug resistance. If ITMs reduced the development and spread of antimalarial drug resistance, this would enhance their usefulness as a malaria control tool. This study examines the impact of insecticide-treated curtains (ITC)used over 6-8 years on the prevalence of antimalarial drug resistance in Burkina Faso. Objectives 2.1 Primary objectives To determine the frequency of in vivo clinical and parasitological failures following treatment of uncomplicated malaria with CQ in children living in villages protected and not protected by insecticide treated curtains (ITC). To determine if children in ITC and non-ITC villages with clinical malaria differ in their ability to clear genetically resistant parasites after treatment with CQ. 2.2 Secondary objectives To determine the proportions of children infected with parasites carrying the pfcrt-76T and pfmdr1-86Y alleles associated with resistance to CQ in villages protected and not protected by ITC. To determine the proportions of children infected with parasites carrying parasites with the dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhps) alleles associated with resistant to SP in ITC and non- ITC protected villages. To relate in vivo clinical and parasitological failure rates to the presence of genotypic markers of resistance to CQ by estimating genotype-failure indices (GFIs) and genotype-resistance indices (GRIs). Methods 3.1 Field work Passive case detection was used to recruit children aged 6-59 months with uncomplicated malaria using a slightly modified version of the standard WHO in vivo method for assessing therapeutic efficacy of anti-malarial drugs .Children seeking care at the selected health centres were screened for eligibility to join the study, enrolled and followed up for 14 days. If a child's axillary temperature was >=37.5 ºC and no obvious cause of fever other than malaria was found on clinical examination, about 500 ml of blood was drawn into a micro-container containing EDTA. Microscopic diagnosis of malaria and measurement of packed-cell volume (PCV) were performed immediately after samples were received in the laboratory. After enrolment, further clinical examinations were performed on days 1, 2, 3, 7, and 14. In addition, the caretakers were advised to bring children back to the health centre at any time between day 1 and day 14 if the child's condition did not improve. Thick and thin blood films and filter paper blood spots were prepared on days 0, 3, 7, 14 and at unscheduled visits. Treatment of children and treatment outcome A standard treatment with CQ was administered to children with uncomplicated malaria. The treatment dosing was 25 mg/kg body weight of CQ over 3 days; 10 mg/kg on days 0, 1 and 5 mg/kg on day 2. Treatment was administered at the clinic under the supervision of a nurse. Outcomes for the in vivo trial were classified according to the WHO clinical and parasitological assessment system Prevalence of pfcrt-76 and pfmdr1-86 mutations in the community A cross-sectional survey was conducted to estimate the prevalence of pfcrt-76 and pfmdr1-86 mutations in asymptomatic children. Random samples of children aged 6 to 59 months and children aged 5 years to 14 years were selected per village. Thick and thin blood films and filter paper blood spots were prepared from a finger-prick. Estimation of the entomological inoculation rate A cross-sectional survey was conducted at the peak period of malaria transmission (September 2002) for the estimation of the EIR. Catches were performed using CDC light traps. An ELISA test was used to detect the presence of P. falciparum circumsporozoite protein (CSP). Socio-economic and health seeking behaviour survey In 2003, a survey was performed in a random sample of 20 compounds in each village to collect data on health seeking behaviour, socio-economic and demographic features of the study population including the frequencies of population movements between villages. 3.2 Laboratory methods Thick and thin blood films were stained with Giemsa stain (3%) for 45 minutes. Asexual parasites and gametocytes of P. falciparum were counted against 400 white blood cells. For molecular biology analyses, DNA was extracted from pre, post-treatment and cross-sectional survey filter paper blood spots using chelex. DNA was amplified by nested PCR to detect mutations at pfcrt-76. Nest 2 PCR products were digested by Apo I endonuclease restriction enzyme and electrophoresed onto a 3% agarose. Sequence-specific oligonucleotide probing (SSOP) was performed to detect the presence of pfmdr1-86 mutation. Mutations at dhfr (51, 59 and 108) and at dhps ( 437 and 540) were also detected by SSOP. MSP2 gene polymorphisms were studied by PCR to differentiate recrudescence from new infections. 3.3 Sample size and power With 18 communities (9 per group), the study would have 80% power to detect, at the 5% significance level, a 50% decrease in clinical failure rate in eligible children. This number of communities would also permit the detection of a 40% decrease in parasitological failure rate in eligible children with the same power, and at least 60% and 40% increases in clinical and parasitological failure rates, at 5% significance level, in children carrying parasites with CQ resistant genotypes before CQ treatment was started. 3.4 Data processing and analyses Two data clerks independently entered data onto computers using EPIINFO version 6.0. Analyses were performed using STATA (Release 8.2, www.stata.com). The study main endpoints were examined using Generalized Estimating Equations regression model 3.5 Community approval This was obtained after meetings with community leaders to explain the objectives of the study and what it involved. In addition to community consent, individual signed informed consent was obtained from caretakers of children before enrolment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria
Keywords
Transmission intensity, Insecticide-treated materials, antimalarial drug resistance

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
1035 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Chloroquine
Primary Outcome Measure Information:
Title
Clinical and parasitological failure rates by day 14
Title
Prevalence of pfcrt-76T, pfmdr1-86Y before treatment
Secondary Outcome Measure Information:
Title
Proportion of children who cleared parasites carrying pfcrt-76T and pfmdr1-86Y alleles.
Title
Prevalence of dhfr-51, 59, 108 and dhps-437, 540

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
59 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 6 and 59 months Mono infection with P.falciparum malaria, with parasitaemia in the range of 1,000 to 150,000 parasites per ml Absence of danger signs or signs of severe malaria. Axillary temperature >= 37.5 ºC. Absence of signs of severe malnutrition. Absence of any obvious cause of fever other than malaria. No history of allergy to CQ. Willingness to return to the health facility for follow-up. Informed consent obtained from the caretaker of the child Exclusion Criteria: Danger signs of severe or complicated malaria, persisted vomiting. Received treatment with an antimalarial drug other than CQ in the last 2 weeks. Caretaker did not sign the consent form
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simon Cousens, PhD
Organizational Affiliation
London School of Hygiene and Tropical Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Brian M Greenwood, FRCP FRS
Organizational Affiliation
London School of Hygiene and Tropical Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Diadier Diallo, MsC
Organizational Affiliation
Centre national de recherche et de formation sur le paludisme
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Colin Sutherland, PhD
Organizational Affiliation
London School of Hygiene and Tropical Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre National de Recherche et de Formation sur le Paludisme
City
Ouagadougou
State/Province
Kadiogo
ZIP/Postal Code
2208
Country
Burkina Faso

12. IPD Sharing Statement

Learn more about this trial

Impact of Insecticide-treated Curtains on Antimalarial Drug Resistance

We'll reach out to this number within 24 hrs